AbbVie released first data tied to its $350 million amylin program showing nearly 10% mean weight loss at 12 weeks in certain patients, while Regeneron’s Chinese partner reported Phase 3 results that mirrored efficacy seen with Zepbound. The early wins de‑risk late‑stage obesity franchises and likely accelerate commercialization planning, competitive positioning and pricing discussions. Both programs target the rapidly evolving obesity market where incremental efficacy, dosing convenience and safety profiles will determine payer access and uptake.